| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2006 | EP1704150A1 2,3-dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| 09/27/2006 | EP1704149A1 Triaza-cyclopenta[cd]indene derivatives |
| 09/27/2006 | EP1704148A1 Novel fused pyrrolocarbazoles |
| 09/27/2006 | EP1704147A1 PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM |
| 09/27/2006 | EP1704146A1 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| 09/27/2006 | EP1704145A1 Selective kinase inhibitors |
| 09/27/2006 | EP1704142A1 Protease inhibitors |
| 09/27/2006 | EP1704141A1 Prostaglandin nitrooxyderivatives |
| 09/27/2006 | EP1704140A1 Synthesis of optically pure (r)-5-(2-aminopropyl)-2-methoxybenzenesulphonamide |
| 09/27/2006 | EP1704139A1 DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS |
| 09/27/2006 | EP1704136A1 Gossypol derivatives, production method thereof and uses of same |
| 09/27/2006 | EP1704135A1 Propofol analogs, process for their preparation, and methods of use |
| 09/27/2006 | EP1703919A1 Vaginal compositions for treating infections |
| 09/27/2006 | EP1703918A2 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 09/27/2006 | EP1703913A2 Use of ribose in recovery from anaesthesia |
| 09/27/2006 | EP1703912A1 Compounds for the inhibition of undesired cell proliferation and use thereof |
| 09/27/2006 | EP1703911A1 Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
| 09/27/2006 | EP1703910A2 Treatment of aromatase inhibitor therapy-related osteoporosis |
| 09/27/2006 | EP1703909A1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 09/27/2006 | EP1703908A1 Aryl sulfonamide compounds and uses related thereto |
| 09/27/2006 | EP1703907A2 Compositions and methods to treat recurrent medical conditions |
| 09/27/2006 | EP1703906A1 Immuno inhibitory pyrazolone compounds |
| 09/27/2006 | EP1703905A1 Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors |
| 09/27/2006 | EP1703904A2 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof |
| 09/27/2006 | EP1703903A1 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence |
| 09/27/2006 | EP1703902A2 Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
| 09/27/2006 | EP1703901A2 Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol |
| 09/27/2006 | EP1703900A1 Controlled release ketoprofen formulation |
| 09/27/2006 | EP1703898A2 Ziprasidone formulations |
| 09/27/2006 | EP1703897A2 Method for producing keto-l-gulonic acid spray granules |
| 09/27/2006 | EP1703896A2 Pharmaceutical compositions comprising midazolam in a high concentration |
| 09/27/2006 | EP1703894A1 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| 09/27/2006 | EP1703892A2 Uv light-stable semi-solid transdermal systems comprising a photosensitive active agent and an uv-absorbing component |
| 09/27/2006 | EP1703797A2 TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF |
| 09/27/2006 | EP1635809A4 Resolution of alpha-(phenoxy)phenylacetic acid derivatives |
| 09/27/2006 | EP1624878B1 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
| 09/27/2006 | EP1617834B1 Use of a pharmaceutical composition containing lactic acid or lactate and potassium for treating brain edema or brain injury |
| 09/27/2006 | EP1615638B1 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy |
| 09/27/2006 | EP1594840B1 Piperidine-benzenesulfonamide derivatives |
| 09/27/2006 | EP1565445B1 Process for the preparation of imidazolyl compounds |
| 09/27/2006 | EP1560575B1 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
| 09/27/2006 | EP1545218A4 Full range nutritional supplements from plant materials and methods for their manufacture |
| 09/27/2006 | EP1534687B1 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| 09/27/2006 | EP1511496B1 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| 09/27/2006 | EP1501826B1 Substituted indoles as alpha-1 agonists |
| 09/27/2006 | EP1486208B1 Use of a novel preventive for infections |
| 09/27/2006 | EP1471890B1 Pharmaceutical dosage form for mucosal delivery |
| 09/27/2006 | EP1461062B1 Composition and method for treating chronic allograft rejection |
| 09/27/2006 | EP1458716B1 Bicyclic n-arylamides |
| 09/27/2006 | EP1450792B1 Benzazole derivatives for the treatment of scleroderma |
| 09/27/2006 | EP1421078B1 Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| 09/27/2006 | EP1404341B1 Active substance combination for medicamentous therapy of nicotine dependency |
| 09/27/2006 | EP1395590B1 Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists |
| 09/27/2006 | EP1383757B1 Antagonists of mcp-1 function and methods of use thereof |
| 09/27/2006 | EP1377580B1 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
| 09/27/2006 | EP1374899B1 Remedies for post-traumatic stress disorder |
| 09/27/2006 | EP1368008B1 Transdermal therapeutic system for the administration of the partial dopamine-d2 agonist aripiprazol |
| 09/27/2006 | EP1337521B1 Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
| 09/27/2006 | EP1335906B1 Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
| 09/27/2006 | EP1322293B1 Modified release formulation |
| 09/27/2006 | EP1286967B1 Cyclohexane derivatives and their use as therapeutic agents |
| 09/27/2006 | EP1272907B1 Compliance tracking method |
| 09/27/2006 | EP1265605B1 Pharmaceutical compositions comprising beta-turn peptidomimetic cyclic compounds |
| 09/27/2006 | EP1251832B1 Shell-and-core dosage form approaching zero-order drug release |
| 09/27/2006 | EP1246622B1 Novel substituted benzimidazole dosage forms and method of using same |
| 09/27/2006 | EP1173222B1 Conjugate having a cleavable linkage for use in a liposome |
| 09/27/2006 | EP1140733B1 Process and products of purification of anhydrosugar alcohols |
| 09/27/2006 | EP1140196B1 pharmaceutical solutions comprising triphenylethylene antiestrogens |
| 09/27/2006 | EP1123088B1 Sustained-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 09/27/2006 | EP1000079B1 New formulation |
| 09/27/2006 | EP0983765B1 Preventives or remedies for diseases in association with vascular functional anomaly relating to insulin resistance |
| 09/27/2006 | EP0957921B1 17alpha-dihydroequilenin for preventing neurodegeneration and cognitive dysfunction |
| 09/27/2006 | EP0951286B1 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
| 09/27/2006 | CN1839206A RNA interferases and methods of use thereof |
| 09/27/2006 | CN1839204A Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof |
| 09/27/2006 | CN1839146A New delta-15-d-homosteroid compounds having an androgenic effect |
| 09/27/2006 | CN1839139A Proteasome inhibitors and methods of using the same |
| 09/27/2006 | CN1839138A Substituted furochromene compounds of antiinflammatory action |
| 09/27/2006 | CN1839137A Substituted furochromenes, preparation thereof and their antiinflammatory action |
| 09/27/2006 | CN1839135A Tricyclic delta-opioid modulators |
| 09/27/2006 | CN1839134A [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| 09/27/2006 | CN1839133A Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| 09/27/2006 | CN1839132A N3-substituted imidazopyridine-derivatives as C-KIT inhibitors |
| 09/27/2006 | CN1839131A Azolidinecarbonitriles and their use as DPP-IV inhibitors |
| 09/27/2006 | CN1839130A N-substituted pyrazolyl-amidyl-benzimidazolyl C-KIT inhibitors |
| 09/27/2006 | CN1839129A Novel n-substituted indolyl-3-glyoxylic acid amides, use thereof as a medicament, and method for the production thereof |
| 09/27/2006 | CN1839128A Mitotic kinesin inhibitors |
| 09/27/2006 | CN1839127A Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
| 09/27/2006 | CN1839126A Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| 09/27/2006 | CN1839125A (3R,4R)-trans-3,4-diarylchroman derivatives with estrogenic activity |
| 09/27/2006 | CN1839124A Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| 09/27/2006 | CN1839121A Hydroxamic acid compounds and methods of use thereof |
| 09/27/2006 | CN1839114A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 09/27/2006 | CN1839102A An electric desalination method and structure of a spiral winding electric desalination device |
| 09/27/2006 | CN1838969A Preparation for percutaneous/permucosal absorption |
| 09/27/2006 | CN1838961A Use of s1p |
| 09/27/2006 | CN1838960A Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for local application |
| 09/27/2006 | CN1838959A Dosing schedule for ERBB2 anticancer agent |
| 09/27/2006 | CN1838958A Methods of treating COPD and pulmonary hypertension |
| 09/27/2006 | CN1838957A Chemokine inhibiting piperazine derivatives and their use to treat myocarditis |